Brandon E. Kremer

South College — United States

Medicine · Health Sciences

20h-index2.3kcitations106works6.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(47), Protein Degradation and Inhibitors(40), Peptidase Inhibition and Analysis(18), Lung Cancer Treatments and Mutations(10), Chronic Lymphocytic Leukemia Research(10)

Publications106 total

Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2025Open Access
Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change
Blood·2025Open Access
Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Blood·2025Open Access
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
The Lancet Haematology·2025· 1 cited
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
Annals of Oncology·2025· 6 cited
Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study
Targeted Oncology·2025Open Access
MM-1045: Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
POSTER: MM-1045 Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-1486 Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Clinical Lymphoma Myeloma & Leukemia·2025
MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Clinical Lymphoma Myeloma & Leukemia·2025
MM-1486: Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).
Journal of Clinical Oncology·2025· 1 cited
DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.
Journal of Clinical Oncology·2025· 1 cited
Belantamab treatment of multiple myeloma: Results from part 1 of the first-in-human phase 1/2 DREAMM-20 trial.
Journal of Clinical Oncology·2025
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.
Journal of Clinical Oncology·2025
page 1 of 6Next →

Frequent Co-authors

Hang Quach(13), Suzanne Trudel(13), María‐Victoria Mateos(10), Ira Gupta(10), Arindam Dhar(9), Geraldine Ferron‐Brady(9), Meletios Α. Dimopoulos(8), Vladimir Vorobyev(8), Paweł Robak(8), Kazuhito Suzuki(8), Kristin Morris(8), Kihyun Kım(7), Michèle Cavo(7), Thierry Horner(7), Olena Barbash(6), Joanna Opalińska(6), Rocío Montes de(6), Sosana Delimpasi(6), Neal Sule(5), Ivan Špıčka(5)